EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study

Myrthe Y C van der Heide iD, Tom E Verstraelen iD, Freyja H M van Lint iD, Laurens P Bosman iD, Remco de Brouwer iD, Virginnio M Proost iD, Esmée van Drie iD, Karim Taha iD, Aeilko H Zwinderman iD, Cathelijne Dickhoff, Bas A Schoonderwoerd, Tjeerd Germans iD und 7 weitere

Europace · 30.03.2024 · 26 (4)

DOI: 10.1093/europace/euae069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, online erschienen am 01.04.2024. Verfasst von Myrthe Y C van der Heide und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Arrhythmias, Cardiac, Defibrillators, Implantable. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PLN Foundation, Netherlands Cardiovascular Research Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Recently, a genetic variant-specific prediction model for phospholamban (PLN) p.(Arg14del)-positive individuals was developed to predict individual major ventricular arrhythmia (VA) risk to support decision-making for primary prevention implantable cardioverter defibrillator (ICD) implantation. This model predicts major VA risk from baseline data, but iterative evaluation of major VA risk may be warranted considering that the risk factors for major VA are progressive. Our aim is to evaluate the diagnostic performance of the PLN p.(Arg14del) risk model at 3-year follow-up. Methods and results We performed a landmark analysis 3 years after presentation and selected only patients with no prior major VA. Data were collected of 268 PLN p.(Arg14del)-positive subjects, aged 43.5 ± 16.3 years, 38.9% male. After the 3 years landmark, subjects had a mean follow-up of 4.0 years (± 3.5 years) and 28 (10%) subjects experienced major VA with an annual event rate of 2.6% [95% confidence interval (CI) 1.6–3.6], defined as sustained VA, appropriate ICD intervention, or (aborted) sudden cardiac death. The PLN p.(Arg14del) risk score yielded good discrimination in the 3 years landmark cohort with a C-statistic of 0.83 (95% CI 0.79–0.87) and calibration slope of 0.97.

Conclusion

The PLN p.(Arg14del) risk model has sustained good model performance up to 3 years follow-up in PLN p.(Arg14del)-positive subjects with no history of major VA. It may therefore be used to support decision-making for primary prevention ICD implantation not merely at presentation but also up to at least 3 years of follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arrhythmias, CardiacDefibrillators, ImplantableFemaleHumansMaleCalcium-Binding ProteinsDeath, Sudden, CardiacReproducibility of ResultsRisk FactorsAdultMiddle AgedPhospholamban

Stichwörter der Autor:innen

CardiomyopathyICD implantationLandmark analysisPLN p.(Arg14del) risk modelPhospholamban

Substanzen

Calcium-Binding ProteinsPhospholamban

Autor:innen und Institutionen

  • Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.
  • Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.
  • Department of Genetics, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, Netherlands.
  • Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, University of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands.
  • Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands.
  • Department of Clinical Epidemiology and Biostatistics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.

ORCID-Profile: Myrthe Y C van der Heide, Tom E Verstraelen, Freyja H M van Lint, Laurens P Bosman, Remco de Brouwer, Virginnio M Proost, Esmée van Drie, Karim Taha, Aeilko H Zwinderman, Tjeerd Germans, Arjan C Houweling, Juan R Gimeno-Blanes, Paul A van der Zwaag, Rudolf A de Boer, Moniek G P J Cox, J Peter van Tintelen, Arthur A M Wilde

Förderung

  • PLN Foundation
  • Netherlands Cardiovascular Research Initiative

Zitieren

APA

van der Heide, M. Y. C., Verstraelen, T. E., van Lint, F. H. M., Bosman, L. P., de Brouwer, R., Proost, V. M., van Drie, E., Taha, K., Zwinderman, A. H., Dickhoff, C., Schoonderwoerd, B. A., Germans, T., Houweling, A. C., Gimeno-Blanes, J. R., van der Zwaag, P. A., de Boer, R. A., Cox, M. G. P. J., van Tintelen, J. P., & Wilde, A. A. M. (2024). Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study. Europace, 26(4). https://doi.org/10.1093/europace/euae069

Vancouver

van der Heide MYC, Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, et al. Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study. Europace. 2024;26(4). doi:10.1093/europace/euae069

BibTeX
@article{vanderHeide2024,
  author = {van der Heide, Myrthe Y C and Verstraelen, Tom E and van Lint, Freyja H M and Bosman, Laurens P and de Brouwer, Remco and Proost, Virginnio M and van Drie, Esmée and Taha, Karim and Zwinderman, Aeilko H and Dickhoff, Cathelijne and Schoonderwoerd, Bas A and Germans, Tjeerd and Houweling, Arjan C and Gimeno-Blanes, Juan R and van der Zwaag, Paul A and de Boer, Rudolf A and Cox, Moniek G P J and van Tintelen, J Peter and Wilde, Arthur A M},
  title = {Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study},
  journal = {Europace},
  year = {2024},
  volume = {26},
  number = {4},
  doi = {10.1093/europace/euae069}
}
Kostenlos starten →